n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, December 28th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

First Foods Group, Inc. (FIFG)

OTC Markets, TradingView, and MarketWatch reported on First Foods Group, Inc. (FIFG), and today we report on the Company, here at the QualityStocks Daily Newsletter.

First Foods Group, Inc. has growing interests in the food and food service industry. The Company provides management services and funding options for new foodservice brands and menu concepts. Additionally, it is growing its new concepts by way of proprietary development and through mergers, acquisitions, and licensing arrangements. First Foods Group lists on the OTC Markets Group’s OTCQB.

On March 3, 2017, the Company announced the effectuation of its formal name change from Litera Group, LLC, to First Foods Group, Inc. The Company’s Board, as well as its majority shareholder, approved the name change on February 15, 2017.

First Foods Group earlier signed cannabis business expert Mr. Robert Hunt, Esq. to identify opportunities in the legal cannabis industry where First Foods' management, expertise, and relationships could have substantial effect. Mr. Hunt is one of the distinguished consultants in the legalized marijuana industry. He has been instrumental in many of the best known and most successful cannabis businesses in operation today.

First Foods Group announced this past July that veteran investment banker, Mr. Robert C. Kanuth, Jr. accepted the position of Vice President of Finance for the Company. Mr. Kanuth, Jr. will administer the newly established First Foods Financing division. His division will identify, negotiate, as well as officiate all First Foods Group's capital raising efforts. This includes new franchise acquisitions and client financing.

He is a distinguished investment banker who founded and directed the highly successful Cranston Securities in the mid-1970's. Mr. Kanuth, Jr. then established Cranston Development, funding projects that restored and revitalized such cities as Richmond, Virginia; Savannah, Georgia; and Pittsburgh, Pennsylvania.

In April of this year, First Foods Group entered into a binding term sheet with world renowned chocolatier and entrepreneur Mr. Oded Brenner. This is to fully develop Mr. Brenner’s new chocolate based retail concept.

This new venture will be jointly owned by First Foods Group and Mr. Brenner. Initial plans are to launch two flagship stores in New York, New York, and also to immediately leverage several multi-unit worldwide franchising opportunities.

Last month, First Foods Group provided a shareholder update. The Company’s recently incorporated Holy Cacao subsidiary has been funded. In addition, it has started operations. Holy Cacao is marketing premium chocolate products created and packaged by Holy Cacao consultant, Oded Brenner, founder of "Max Brenner, Chocolate by the Bald Man," for the legal cannabis sector.

Mr. Rob Hunt is leading Holy Cacao's efforts to gain traction in legalized states. Mr. Hunt has already introduced the Company’s innovative product line to some of the largest players in the edibles sector. He is currently negotiating manufacturing and distribution deals, anticipating product launch in Q1 2018.

First Foods Group, Inc. (FIFG), closed Thursday's trading session at $0.51, even for the day. The average volume for the last 60 days is 1,312 and the stock's 52-week low/high is $0.12/$2.84.

Table Trac, Inc. (TBTC)

FeedBlitz, BUYINS.NET, and M2 Communications reported previously on Table Trac, Inc. (TBTC), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Table Trac, Inc. is a developer and provider of casino information and management systems. These systems automate and monitor the operations of casinos. The Company has systems installed in North America, South America, and Central America, and also the Caribbean. Established in 1995, Table Trac has its head office in Minnetonka, Minnesota. The Company also has a South America office in Envigado, Colombia.

The TableTrac™ table games management system is a patented solution. TableTrac™ provides table games managers and gaming operators with all the modules needed to manage and run a table games Pit. These include modules from credit fills and reporting to patron management and promotions.

Furthermore, the CasinoTrac™ casino management system provides a total complement of all the modules vital to ensure floor operations, real-time floor monitoring, daily revenue auditing, and managerial accounting and players club operations for any size casino.

In addition, the design of Table Trac’s KioskTrac™ is to reward play and boost visitation. KioskTrac™ provides operators with a vehicle to grow revenues. This is from “text-to-win” and campaigns, to email and direct mail.

Table Trac signed 12 new customer contracts in 2016. The Company expanded its presence in California, and Oklahoma. Additionally, Table Trac delivered its first systems in Texas and Washington.

At the end of 2016, the Company had casino management systems, table games management systems, and ancillary products installed with continuing support and maintenance contracts with numerous casino operators around the world. It also received gaming licenses in Colorado and Nevada.

Red Lake Gaming Enterprises has installed new casino management systems from Table Trac at its three first-class gaming properties in northern Minnesota. Red Lake Gaming Enterprises has provided premier gaming entertainment at its northern Minnesota casino locations since 1992.

Starting in 2004 they called on CasinoTrac systems to help. After a short hiatus, Table Trac has been selected to return to Red Lake Gaming and provide casino management systems.

Furthermore, Festival Casino has contracted with Table Trac to install their CasinoTrac online slot management system. This brings to six the number of Central America casinos selecting Table Trac's reliable and user-friendly system in 2017. Festival Casino is in Perez Zeledon, Costa Rica. CasinoTrac's system will add customer conveniences and a winning player club for the exotic Casino location.

Table Trac, Inc. (TBTC), closed Thursday's trading session at $2.40, even for the day. The average volume for the last 60 days is 1,188 and the stock's 52-week low/high is $0.51/$2.55.

AXIM Biotechnologies, Inc. (AXIM)

TopPennyStockMovers, CFN Media Group, Promotion Stock Secrets, and SmallCapVoice reported earlier on AXIM Biotechnologies, Inc. (AXIM), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

AXIM Biotechnologies, Inc. is a biotechnology company focusing on the research, development, and production of cannabis-based pharmaceutical, nutraceutical, and cosmetic products. The Company discovers and brings to market innovative solutions via research and development (R&D), strategic partnerships, and acquisitions through setting the green standard in the industrial hemp industry. Medical Marijuana, Inc. is a major investor in AXIM. AXIM Biotechnologies is headquartered in New York, New York.

The Company’s emphasis is on unique proprietary delivery mechanisms for the introduction of cannabinoids and finding solutions for conditions for which there is presently no effective treatment. AXIM is advancing its patented controlled-release cannabinoid gum in studies encompassing a number of indications. AXIM’s flagship CanChew Plus® contains 10mg of cannabidiol (CBD) obtained from industrial hemp plants.

AXIM’s pipeline of Intellectual Property (IP) protected cannabinoid-based products additionally include MedChew Rx™. This THC/CBD cannabinoid controlled-release chewing gum is to address pain and muscle spasticity in multiple sclerosis (MS) patients. This pioneering invention is on course to be fully registered by the EMA and the Food and Drug Administration (FDA) by the end of 2017. It is the world’s first patented cannabinoid controlled-release chewing gum.

In addition, AXIM’s products include RENECANN™ - the world’s first cannabigerol (CBG)-based skincare product line. Moreover, its products include ORAXIMAX™ - the world’s first CBG-based oral care product line; Suppocann™ - a suppository cannabinoid-release product for GI conditions including IBD, IBS and Crohn’s disease; and Ophthocann™ and Cannbleph™ - cannabinoid-based products for the reducing of intraocular pressure and for the relief of conjunctivitis.

The Company’s IP portfolio now includes two fully issued patents – one patent permitting the use of CBD (cannabidiol) in controlled-release, functional chewing gum, and another patent for chewing gum containing natural and synthetic cannabinoids for the treatment of pain, and 15 patent applications in different stages of approval.

In November, AXIM® Biotechnologies announced clinical trial results from its first Phase II pilot trial for the treatment of irritable bowel syndrome (IBS) with its CanChew +® CBD (cannabidiol) functional, controlled release chewing gum. The study was conducted at Wageningen University in The Netherlands. It was a randomized, placebo controlled, double-blind, cross-over trial aimed at investigating acceptance and overall pain reduction.

Study results indicate that CanChew+® was well tolerated by the IBS patients. In addition, no significant adverse side effects were observed by any participants of the trial. All patients who participated in the study experienced decrease in their levels of pain score.

Earlier this month, AXIM® Biotechnologies announced that it successfully completed a pre-investigational New Drug Application (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for a dronabinol-based functional, controlled-release chewing gum product the Company is developing to help treat patients with chemotherapy-induced nausea and vomiting and HIV/AIDS patients experiencing appetite and weight loss. AXIM will now start preparing its IND filing to the FDA for this new chewing gum product, referencing Marinol®, one of the FDA-approved, dronabinol-based drugs available in the United States.

AXIM Biotechnologies, Inc. (AXIM), closed Thursday's trading session at $8.92, up 12.91%, on 89,942 volume with 400 trades. The average volume for the last 60 days is 18,806 and the stock's 52-week low/high is $4.45/$19.80.

Titan Medical, Inc. (TITXF)

BullRally, PennyStockVille, StockRich, OTC Markets Group, CoolPennyStocks, HotOTC, MadPennyStocks, and Sharemkt Tips reported earlier on Titan Medical, Inc. (TITXF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Titan Medical, Inc. centers on the design, development, and commercialization of a robotic surgical system for application in minimally invasive surgery (MIS). Currently under development, the Company’s SPORT Surgical System includes a surgeon-controlled robotic platform that features multi-articulating instruments for performing MIS procedures via a single port. A medical device company, Titan Medical is based in Toronto, Ontario. The Company lists on the OTC Markets Group’s OTCQB.

The SPORT Surgical System is a unique single incision robotic surgical system. It has undergone development based on clinical user needs. It is covered by 14 patents and 37 pending applications.

The SPORT Surgical System provides access to underserved market segments, such as ambulatory surgery centers. Regarding Open Display, the 3D high definition 32-inch display provides a first-rate balance of surgical immersion and situational awareness in the Operating Room (OR).

Titan’s surgical system includes a workstation that provides a surgeon with an advanced ergonomic interface to the robotic platform for controlling the instruments and also provides a 3D high-definition endoscopic view inside a patient's body. The design of the SPORT system is to enable surgeons to perform a comprehensive set of general abdominal, gynecologic, urologic, and colorectal procedures. The design of the system is for improved clinical capabilities, operating room efficiency, and hospital economics.

Titan Medical has completed initial formative human factors studies for its SPORT single port robotic surgical system. Formative human factors studies involve the evaluation of prototypes by expert users that focus on simulated task exercises vital to product safety. Titan Medical is planning to commercialize its single incision surgical system - first in Europe and then in the United States.

Earlier this month, Titan Medical announced the granting of Canadian Patent CA 2973227 and CA 2973235. These patents are related generally to control methods for robotic surgical systems. This includes the provision of select autonomous control and safety functions that enable optimal controllability of robotic instruments during use.

The methods describe alignment control of robotic instruments, including snake-like or multi-articulated instruments as utilized in the SPORT system that are important for facilitating movement within the abdomen. Corresponding patent applications are pending in the United States and Europe. Titan anticipates future issuances in numerous jurisdictions.

Last week, Titan Medical reported the successful first use of its SPORT Surgical System in Europe. These studies in general and urologic surgery at the Institute of Image-Guided Surgery at the Institut Hospitalo-Universitaire de Strasbourg, France are part of the feasibility and validation studies intended to support regulatory submissions.

Mr. David McNally, Titan Medical President and Chief Executive Officer, said, “After our installation of the SPORT system at IHU Strasbourg earlier this month, surgeons have now successfully completed the first preclinical single-port robotic surgeries in Europe using the SPORT system. We are honored that highly-regarded surgeons …directed and performed a variety of abdominal, oncologic and urologic procedures. These first-use studies provide valuable insight into procedures we may focus on during commercialization.”

Titan Medical, Inc. (TITXF), closed Thursday's trading session at $0.295, down 1.67%, on 577,137 volume with 178 trades. The average volume for the last 60 days is 1,626,400 and the stock's 52-week low/high is $0.096/$0.55.

Mikros Systems Corp. (MKRS)

OTCEquity, PennyStocks24, AwesomeStocks, Wall Street Mover, PricelessPennyStocks, Promotion Stock Secrets, Marketbeat.com, Fast Money Alerts, Actual Gains, AddictivePennyStocks, Chatter Box Stocks, StockLockandLoad, PennyStockRumors.net, StockRockandRoll, StockBomb.com, ResearchOTC, and OTPicks reported on Mikros Systems Corp. (MKRS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Mikros Systems Corp. is a provider of advanced maintenance and monitoring solutions for mission-critical systems. The Company is an advanced technology enterprise that designs and manufactures specialized electronic systems for the Department of Defense. Its chief business is to pursue and obtain contracts from the Department of Homeland Security, the U.S. Navy, and other governmental authorities. The Company is headquartered in Princeton, New Jersey, and has its Manufacturing and Depot Center in Largo, Florida.

Mikros produces advanced maintenance systems for the Navy. These include the ADEPT Maintenance Automation Workstation and the ADSSS Condition Based Maintenance system for the Littoral Combat Ship. ADEPT systems are in use daily for performance optimization of advanced radar systems.

The Company has developed, delivered, and installed military-grade equipment to Federal customers’ for more than 30 years. Its capabilities include technology management, electronic systems engineering and integration, radar systems engineering, command, control, communications, computers and intelligence systems engineering, and communications engineering.

Mikros Systems’ Lifecycle Support capability is focused on ensuring the systematic interactions between Integrated Logistics Support (ILS), Depot, and Field Support activities are integrated to accomplish the highest levels of system readiness. The Company purchased certain software products, intellectual property (IP) and related assets from VSE Corp. The main software programs purchased by Mikros are the Prognostics Framework (PF) and Diagnostic Profiler (DP) programs.

The Diagnostic Profiler software is used globally by many multinational companies for optimized maintenance of varied product lines. Diagnostic Profiler is also used by the U.S. Air Force for depot test programs.

Prognostics Framework is used by the U.S. Army for many missile defense systems. These software products provide Mikros Systems with the opportunity to service commercial customers and additional Department of Defense customers outside the Navy.

In September 2017, Mikros Systems announced that it received the second production order awarded under its recent multi-year $35M contract with the Naval Surface Warfare Center in Crane, IN. This order covers new production deliveries of Mikros' Adaptive Diagnostic Electronic Portable Testset (ADEPT). It is valued at $2.4 million. The ADEPT units will be produced at the Mikros Manufacturing and Depot Center in Largo, FL.

Mikros has successfully completed the first ship and shore installation and testing of its ADEPT Distance Support Sensor Suite (ADSSS) on the Littoral Combat Ship USS INDEPENDENCE (LCS 2). As installed on LCS 2, ADSSS will utilize the Company’s proprietary model-based Prognostics Framework technology to monitor combat system elements to detect and predict on-ship system failures and apply predictive analytics to on-shore systems to detect broader maintenance trends and patterns across the fleet.

ADSSS Program Manager, Lori Ogles, said earlier in December, "Mikros has been a proud partner of the U.S. Navy for over fifteen years. We are honored to continue to support the readiness of U.S. Navy combat systems with our condition-based maintenance solution and we look forward to expanding the ADSSS technology to additional LCS and U.S. Naval platforms."

Mikros Systems Corp. (MKRS), closed Thursday's trading session at $0.49, even for the day, on 9,800 volume with 5 trades. The average volume for the last 60 days is 20,683 and the stock's 52-week low/high is $0.205/$0.63.

Pivot Pharmaceuticals, Inc. (PVOTF)

OTC Markets and MarketWatch reported on Pivot Pharmaceuticals, Inc. (PVOTF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

An emerging biopharmaceutical enterprise, Pivot Pharmaceuticals, Inc. is developing novel treatments to address unmet medical needs. The Company's pipeline targets indications such as cancer supportive care, pain and inflammation, women’s sexual dysfunction, dermatology, and eye disease. Pivot Pharmaceuticals is based in Vancouver, British Columbia. Its wholly-owned subsidiary is Pivot Green Stream, Inc. Pivot Pharmaceuticals' shares trade on the OTC Markets Group's OTCQB.

The Company engages in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals and also drug delivery platform technologies. Pivot focuses on the pharmaceutical development of proprietary drug delivery technologies for maifold indications using small molecules, biological, and botanical products to treat unmet medical needs.

The Company has in-licensed BiPhasix™ Transdermal Drug Delivery platform technology for the delivery and commercialization of Cannabinoids, Cannabidiol (CBD), and Tetrahydrocannabinol (THC) based products, for human and animal use.

Pivot’s potential CBD pharmaceutical pipeline includes PVT-011, PVT-0I2, PVT-013, and PVT-014. The Company’s subsidiary, Pivot Green Stream, concentrates on the research and development (R&D) of cannabinoid based nutraceuticals and pharmaceuticals.

Pivot Green Stream’s initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005) and psoriasis (PGS-N007), as well as an oral product (PGS-N001) for cancer supportive care.

Pivot Pharmaceuticals previously signed a Definitive Agreement with Altum Pharmaceuticals, Inc., to acquire the worldwide rights to BiPhasix™ Transdermal Drug Delivery technology for the development and commercialization of Cannabinoids, Cannabidiol (CBD) and Tetrahydrocannabinol (THC) products.

BiPhasix™ can entrap and transport pharmaceutical products through the skin to attain therapeutic benefit in a broad assortment of indications. Studies have shown that BiPhasix™ can substantially enhance the bioavailability of numerous drugs, leading to improved clinical outcomes. The proprietary technology can also serve as an alternative dosage form to injectables through providing less invasive routes of administration, including dermal, transdermal, and nasal, vaginal, ocular, and rectal.

Last week, Pivot Pharmaceuticals and its wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions, announced that Pivot signed a binding Letter of Intent (LOI) to establish a California-based entity (PGS-California) to speed up the monetization of the Ready To Infuse Cannabis (RTIC) technology.

The Company’s plan is to construct manufacturing facilities in legal cannabis markets across North America and Europe, obtain the necessary licensures, and launch products utilizing RTIC technology that transforms cannabis oil into powder for infusion. Pivot Pharmaceuticals will appoint Ross Franklin and Patrick Rolfes to executive leadership roles within PGS-California to help execute its business strategy of conducting research, development and commercialization of cannabinoid-based products.

Yesterday, Pivot Pharmaceuticals announced that it entered into a 45 day standstill period with a TSX listed company to explore a business opportunity of mutual interest and benefit. This may result in a co-research and development program, a product launch and/or commercialization agreement, or some other form of potential partnership. The standstill period will end on February 6, 2018.

Pivot Pharmaceuticals, Inc. (PVOTF), closed Thursday's trading session at $2.296, up 21.48%, on 436,835 volume with 509 trades. The average volume for the last 60 days is 36,057 and the stock's 52-week low/high is $0.035/$2.00.

AG&E Holdings, Inc. (AGNU)

Zacks, MarketWatch, The Business Journal, and Investors Hub reported earlier on AG&E Holdings, Inc. (AGNU), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

AG&E Holdings, Inc. distributes, repairs, and services electronic components to the casino industry in the United States. It is one of the largest suppliers of gaming parts, used machines, and electronic components in the nation. The Company’s distribution chain reaches the Caribbean & Puerto Rico, Canada, and Eastern and Western Europe. The Company’s wholly-owned subsidiary is American Gaming & Electronics, Inc.

AG&E Holdings has its head office in Hammonton, New Jersey. The Company is also strategically located in Las Vegas, Florida, and Illinois.

AG&E Holdings is a global distributor and manufacturer of color video monitors and other related distribution products for an array of markets. These include, but are not limited to, gaming machine manufacturers, casinos, coin-operated video game manufacturers, and other display integrators.

The Company’s American Gaming & Electronics (AGE) is a top parts distributor to the gaming markets. It sells parts and services to greater than 700 casinos in North America. Additionally, AGE sells refurbished gaming machines around the world. AGE also installs and services some brands of gaming machines in casinos in North America.

AGE provides repair service for all types of monitors and JCM bill validators, and sells a total range of products. Products it carries include JCM bill validators, Wells-Gardner monitors and LCDs, Coin Mechanism coin acceptors, and replacement parts for these products, among other products. AGE buys, refurbishes, and also markets used gaming machines out of the New Jersey facility.

On December 1, 2016, AG&E Holdings announced that it completed the acquisition of Advanced Gaming Associates LLC (AGA). AG&E moved certain of its operations to better serve its customers. This included moving its Las Vegas, Nevada facility and fulfillment center to a larger facility located closer to major gaming equipment manufacturers. In addition, it included moving its Florida office to Palm Beach - a more central location for its customers.

American Gaming & Electronics, in association with its Joint Venture (JV) partner, Image Power, signed a daily operations contract with Ocean Downs Casino, Berlin, Maryland. This is a partnership between Churchill Downs, Inc. and the Saratoga Casino. This agreement is for AG&E and Image Power to supply slot technicians to maintain all technical operations on the casino floor.

Last month, AG&E Holdings announced financial results for the quarter ended September 30, 2017. For Q3 Revenues were $3.4 million, up $2.1 million from the comparable year AGO period

Net Loss reduced to $(0.4) million. This is $0.2 million less than the prior year. Year-to date Net Loss reduced to $(1.1) million. This is $1.1 million less than the prior year.

Mr. Anthony Tomasello, Chief Executive Officer and President of AG&E Holdings, said, "We are pleased to announce that along with our revenue growth of 168 percent to $3.4 million in the third quarter, we are continuing to show improvements in our bottom line as compared to 2016. Although we are showing a net loss of $(0.4) million for the third quarter, this is an improvement of $0.2 million when compared to third quarter 2016. As well, we are showing over a $1.1 million improvement when comparing our loss of $(1.1) million in the nine months ended September 30, 2017 to the same period in 2016.”

AG&E Holdings, Inc. (AGNU), closed Thursday's trading session at $0.14, down 11.56%, on 36,003 volume with 7 trades. The average volume for the last 60 days is 16,215 and the stock's 52-week low/high is $0.1054/$0.39.

graphic

The QualityStocks
Company Corner

graphic
graphic

Veritas Pharma, Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP)

The QualityStocks Daily Newsletter would like to spotlight Veritas Pharma, Inc. (VRTHF). Today, Veritas Pharma, Inc. closed trading at $0.7677, up 8.75%, on 2,305,851 volume with 1,272 trades. The stock’s average daily volume over the past 60 days is 155,047 and its 52-week low/high is $0.2032/$0.77.

Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), announces that Health Canada has issued its research and development subsidiary, Cannevert Therapeutics Ltd. (“CTL”) a dealer licence no. 2018/6970 under Health Canada’s Section 9.2 of the Narcotic Control Regulations (“NCR”) that will allow them to possess, produce, analyze, sale, send, transport, and deliver cannabis, hemp and related products. This is a significant step for CTL in that in conjunction with discovering and developing new therapeutic cannabis strains, it will also be a commercial service provider of chemistry and biological testing services for licensed producers under Health Canada guidelines.

Veritas Pharma, Inc. (CSE: VRT) (OTCQB: VRTHF) is an emerging pharmaceutical and IP development company publicly traded in Canada, the United States and Germany. Through its recently acquired 80 percent stake in Cannevert Therapeutics Ltd., also known as Veritas' R&D arm, the company is clinically profiling various marijuana cultivars to pharmacologically connect unique strains with specific disease conditions. Veritas Pharma's goal is to perform clinical trials to prove the efficacy of the designated lead cannabis strains and to market the clinically effective cultivars as prescription medicines in a fast-track protocol.

Veritas Pharma's management and R&D team comprises decades of pharmaceutical, clinical and scientific research expertise into several key industry leaders. Lui Franciosi, PhD, who has over 20 years of experience conducting pharmaceutical and medical device studies in academia and industry, leads the company as its CEO. In addition to a team of trained technicians and students working out of academic facilities, Veritas Pharma is pleased to have a renowned group of scientists on board to lead its research efforts. Team members hold 10 PhDs/MD licenses with expertise in chemistry, pharmacology and clinical trials.

Veritas Pharma's mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research and development path aims to solve the critical need for real science to support claims surrounding medical marijuana. The company's approach, combined with its strategic alliances, will effectively address the medical community's concerns over the complexities of cannabis potency, efficacy, quality and content in the nearly 800 marijuana strains currently known in the world. Opportunities for innovation and scientific advancement related to the field of cannabis therapeutics will accelerate the knowledge base and provide a valuable alternative to the global opioid market that is estimated at nearly U.S. $35 billion. A growing negative opinion regarding the use of opioids for pain will continue to drive the need for alternative medical applications such as those provided by cannabis.

Veritas Pharma's clinical cannabis development pipeline includes R&D for chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder. The strategic alliance formed with Cannevert and its scientists will enable Veritas to be at the forefront of developing new and unique strains of medicinal cannabis. These plants, which they plan to patent protect for a variety of unmet medical needs, are destined to help patients suffering with chronic and debilitating symptoms of a variety of medical issues. Over 250 experiments have been performed so far with another 150 pharmacological and biological studies conducted. Veritas Pharma has also entered into an agreement with Sechelt Organic Marijuana Inc., which has a Licensed Producer application pending with Health Canada, to acquire 100 percent ownership in the company.

Results of the company's research to date illustrate Veritas' unique place in the medical marijuana industry. The company's focus on the biological effect of the actual spectrum of cannabinoids sets Veritas apart as it seeks to patent and protect results-driven strains. Disclaimer

Veritas Pharma, Inc. Blog

Veritas Pharma, Inc. News:

Veritas Pharma Subsidiary Receives Health Canada Dealer Licence

Veritas Hires Medical Director to Advise Physicians & Regulators on the Application of Cannevert’s Experimental Results with Cannabis to Clinical Practice & Public Policy

Veritas’ Research Arm Cannevert Signs a Material Transfer Agreement with the Institute for Medical Cannabis of Puerto Rico

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.42505, up 6.26%, on 106,413 volume with 27 trades. The stock’s average daily volume over the past 60 days is 61,453 and its 52-week low/high is $0.20/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub, Inc. (ORHB) Provides 2017 Business Highlights and Sets Special Warrant Exercise Price

ORHub, Inc. (ORHB) Signs 5-year Revenue Agreement with Nationally Recognized "Top 100" Hospital

ORHub, Inc. (ORHB) Warrants Set to Expire on December 31, 2017

Medical Innovation Holdings, Inc. (MIHI)

The QualityStocks Daily Newsletter would like to spotlight Medical Innovation Holdings, Inc. (MIHI). Today, Medical Innovation Holdings, Inc. closed trading at $0.28, up 30.23%, on 46,695 volume with 11 trades. The stock’s average daily volume over the past 60 days is 65,346, and its 52-week low/high is $0.131/$3.99.

Medical Innovation Holdings, Inc. (MIHI), a Colorado-based publicly traded company, owns and operates strategically aligned healthcare service and product companies focused on the delivery of patient care, management services for physician offices, lab services, and pharma; and non-pharma medicines and alternatives to patients and consumers. Healthcare services are delivered and managed through the company's MSO, 3Point Care. 3Point Care uses virtual telemedicine with a unique customized software and hardware platform as a way of bringing quality medical care to rural and medically underserved areas (MUAs) of the country.

3Point Care provides personalized high-tech, high-touch telemedicine encounters that link virtual health specialty doctors with traditional primary physicians and their patients. This approach helps reduce the cost of care while enhancing the quality of care. The company's telemedicine approach is vastly different from other providers who rely on a monthly subscription to opt in the network and then require an encounter fee by the patient each and every time an on-demand physician is utilized. This approach breaks the continuum of care, relies on symptom-based diagnosis, does not accept insurance, and there is no certainty you are dealing with a licensed practitioner. In summation they are not a medical practice but a contract service to deliver virtual care. Because 3Point Care deploys doctors through an actual medical practice, there is no subscription fee. The company works with anyone and everyone that has insurance including Medicare and Medicaid. It works hand and hand with the patient's primary care physician so the continuum of care is always maintained. Part of the integrated software application enables the processing of insurance claims whereby doctors are paid for their services. This allows deductibles to be captured, allowing the patients to take advantage of medical tax deductions.

TeleLifeMd, a multi-disciplinary specialty healthcare practice with strong experience in telemedicine, is the primary deliverer of patient medical care. 3Point care has a unique and exclusive relationship with TeleLifeMD, acting as its management services organization by providing all levels of service that include scheduling, providing telemedicine hardware and software products and support, processing claims, paying all invoices and payroll incurred by TeleLifeMD, as well as any other service required to operate the practice.

BKare Diagnostics, another wholly owned subsidiary of MIHI, is tasked with delivering medical and health-related services such as laboratory testing, diagnostics, and alternative medicines primarily proven nutraceuticals. Its goal is to eventually infuse these products with 100% CBD/Hemp oil and THC-based oils to create new product categories as the law catches up with the cannabis marketplace. The opportunity to offer workable solutions that solve real health problems outside typical big pharma is very exciting for the company. It sees significant revenue opportunities in this space.

MIHI firmly believes the best way to provide access to high-quality medical care is through support and delivery of evidence-based virtual medicine, commonly known as telemedicine. With 80 million people living in rural, medically underserved areas of the nation, the company is poised to fill a glaring void in the healthcare industry by applying cutting-edge technology and time-tested business practices to deliver real-time care. Among the 16 areas of medical specialties available are cardiology, infertility, gastroenterology, pediatrics and obstetrics.

The company serves a number of constituents and stakeholders interested in reducing the cost of health care while simultaneously increasing the quality of care, improving access to health services for millions of people, and bringing value to company shareholders. Its unique platform incorporates every aspect of a telemedicine visit into a single, comprehensive package. Disclaimer

Medical Innovation Holdings, Inc. Company Blog

Medical Innovation Holdings, Inc. News:

Medical Innovation Holdings, Inc. (OTC: MIHI) Announces a Strategic Arrangement With AeonMD, LLC, a Leading Provider of Wellness Therapies for Physician Offices

Medical Innovation Holdings to be Featured on National Radio Telecasted Tuesday October 24th, 2017 at 10AM ET on Beasley Broadcasting

NetworkNewsWire Announces Publication Highlighting Disruptive Business Models in Growing Telemedicine Sector

Cache Elite Inc. (ILUS)

The QualityStocks Daily Newsletter would like to spotlight Cache Elite Inc. (ILUS). Today, Cache Elite Inc. closed trading at $0.007, up 55.56%, on 1,912,707 volume with 47 trades. The stock’s average daily volume over the past 60 days is 507,735 and its 52-week low/high is $0.0021/$0.06.

Cache Elite Inc. (ILUS) is a forward-thinking technology and service provider. The company provides homeowners with the latest in 3D designs, decorative hardware (http://www.eliteknobs.com), and travel and vacation services. Its foray into travel-related services can be found at the TripWitz website (http://www.tripwitz.com) where its proprietary back-end software, called Internet Travel Management Software, helps TripWitz provide its customers with a distinctive, cost-effective and perfect travel experience that sets it apart from other online travel agencies such as Expedia and Travelocity.

TripWitz provides real-time, dynamically packaged vacation quotes that include airfare, hotels, villas, ground transportation and activities. Every client searching for a smarter way to travel will find TripWitz is able to cut out the stress and frustrations found with other online travel agents. The company provides its intuitive travel services to clients searching vacations possibilities at more than 20,000 destinations around the globe.

TripWitz contracts with over 500,000 hotels and connects with the world's airlines through Google's ITA Gateway software that allows for advanced availability solutions to satisfy millions of queries per second at the lowest possible fares. Seasonal rate fluctuations for many travel services, including ground transportation options, are included in the company's software, giving clients the best possible rates. TripWitz prides itself on giving users a friendly vacation experience that includes access to an experienced vacation destination specialist. Customers are never left to fend for themselves at any point of their vacation experience. TripWitz is also accepting Bitcoins, the international cryptocurrency, as payment for not only flights but vacations as well.

A new report published by Allied Market Research projects the global online travel market will reach an estimated $1,091 billion by 2022, with the Asia-Pacific region expected to witness the highest growth during the forecast period. Travelers are looking for sound help in making travel decisions that fit within their budgets. Younger travelers, those within the 21-31 year age bracket, are seen as a more mobile generation, using social media and smartphones for many of their travel planning and booking needs.

TripWitz is an accredited member of the CCRA (Travel Commerce Network), which connects the company to over 180,000 properties worldwide. TripWitz is also an ARC approval agency. ARC accredited agencies are the most select group of dedicated professionals in the U.S. travel industry and are recognized as having met stringent financial, personnel and security requirements.

The official press release announcing the recent launch of TripWitz can be found at the following link: Cache Elite Inc. (ILUS) Unveils New Venture Into the $341 Billion Travel Industry. Disclaimer

Cache Elite Inc. Blog

Cache Elite Inc. News:

Cache Elite Inc. (ILUS) Engages NetworkNewsWire for Corporate Communications Solutions

Cache Elite Inc. (ILUS) is “One to Watch”

A New Audio Interview with Cache Elite, Inc. CEO, Derrick McWilliams, is now at SmallCapVoice.com

Grey Cloak Tech, Inc. (GRCK)

The QualityStocks Daily Newsletter would like to spotlight Grey Cloak Tech, Inc. (GRCK). Today, Grey Cloak Tech, Inc. closed trading at $0.0053, up 51.43%, on 37,327,848 volume with 305 trades. The stock’s average daily volume over the past 60 days is 8,768,058 and its 52-week low/high is $0.0027/$0.1499.

Grey Cloak Tech, Inc. (OTCQB: GRCK), a Las Vegas, Nevada-based company, aims to expand into the rapidly growing cannabinoid (CBD) market through the pending acquisition of Eqova Life Sciences, which focuses on providing a full spectrum line of clinical-grade hemp oil (CBD) products to the medical practitioner market. Eqova Life Sciences, based in Denver, Colorado, develops its own high quality, branded product line of hemp oil health products, with the offer of producing private labels to qualified partners.

Eqova Life Sciences recently exhibited the company's CBD products at the Integrative Medicine Summit in Denver, Colorado, which was attended by over 200 medical professionals. As part of the exhibition, Eqova Life Sciences also debuted its new CannaBio Salve, an innovative topical salve infused with several aromatic natural oils. The company's formulations combine the scientifically-validated, powerful benefits of cannabinoids in standardized products which are then distributed to patients under the care of qualified health practitioners. All Eqova products are carefully researched and go through rigorous third-party testing before and after marketing, providing the security of a clinical-grade product made in cGMP Compliant Labs located in the United States.

According to The Hemp Business Journal, the CBD products marketplace is projected to grow 700 percent by 2020 with annual sales reaching $2.1 billion. The purchase of Eqova Life Sciences would be a natural fit for the company, which has been looking for a way to build shareholder value by adding acquisitions from the rapidly growing CBD sector. Grey Cloak Tech believes medical practitioners seeking high-quality CBD products represent a vastly underserved market. To date, no other hemp oil company has exclusively focused on providing clinical-grade, full-spectrum hemp oil products to this important segment of the medical community.

Grey Cloak Tech also develops advanced software to overcome costly digital threats, most commonly known as online fraud. Grey Cloak Tech leads the industry with continuous development of the most comprehensive and effective weapons against online security threats. The company's proprietary digital advertising fraud detection software, Fraudlytic, provides a cloud-based, secure platform that monitors Internet traffic in real time, blocking malicious and false clicks, while allowing real consumers to view offers and make purchases. Disclaimer

Grey Cloak Tech, Inc. Blog

Grey Cloak Tech, Inc. News:

Grey Cloak Tech Announces Hiring of Stephen Goldberg as New Chief Marketing Officer for CBD.co

Grey Cloak Tech, Inc. Announces Purchase of CBD.co Domain and Plans to Build a CBD Marketplace

Grey Cloak Tech, Inc. to Introduce CannaBio Salve at MJBizCon in Las Vegas

Bollente Companies, Inc. (BOLC)

The QualityStocks Daily Newsletter would like to spotlight Bollente Companies, Inc. (BOLC). Today, Bollente Companies, Inc. closed trading at $0.78, even for the day, on 2,850 volume with 6 trades. The stock’s average daily volume over the past 60 days is 657 and its 52-week low/high is $0.304/$1.21.

Bollente Companies, Inc. (BOLC) is in the early stages of developing a diverse portfolio of companies, targeting disruptive technologies that positively impact the environment and emerging economies. Their current focus is on high-efficiency electric tankless water heaters, manufactured and sold under "trutankless", a division of Bollente, including a line of economy tankless water heaters sold under the Vero name. Units are available for both residential and commercial application.

The primary Bollente advantage is their use of advanced technology, superior to previous tankless systems, together with a growing U.S. and global market. Traditional water heaters are one of the costliest appliances to operate. The two primary energy sources used in U.S. homes are electric and natural gas, with less than half of U.S. homes having natural gas available. In addition, there are no significant electric whole home tankless manufacturers.

The U.S. Department of Energy now requires tanks of 55 gallons or more to have efficiency levels requiring expensive heat pumps to achieve. Bollente's trutankless electric tankless water heater employs specialized sensors for constant water temperature, solid state electronics, and proprietary software, resulting in one of the most efficient heat exchangers ever produced. The technology includes smart grid and home automation capabilities, remote control and monitoring, and even smartphone alerts. It also allows adjustable custom power management settings, so that users can further enhance energy usage and performance. It is now estimated that tankless heaters used in every home would save over $8 billion annually in the U.S. alone.

By maintaining 99 percent efficiency, Bollente's trutankless heaters use less energy than tank heaters, while providing the convenience of always-hot water. The system only uses power when there is demand, producing water to exact temperature, within one degree, even with sudden changes to input. Wireless apps allow for remote settings, notifications, and monitoring, and models are compatible with existing home automation and energy management systems. The technology also reduces size, for easy location, and the system's self-flushing design provides up to 20+ years of maintenance free operation, significantly reducing upkeep and replacement costs. This becomes an additional environmental benefit since roughly 8 million used water heaters are dumped in landfills every year.

Bollente has also announced the formation of Bollente International, Inc., a wholly-owned subsidiary, for the international production and sale of trutankless systems. Taking advantage of growing interest in their technology, Bollente International is working with an international manufacturing firm for the production and distribution of trutankless systems throughout Europe, Asia, Australia and New Zealand, with the first step being the testing and certification necessary to meet the various international standards.

Bollente has made electric tankless water heating compelling to a major consumer market, both in and outside the U.S., offering economic as well as operational efficiency and convenience, attractive to builders as well as to end consumers. Disclaimer

Bollente Companies, Inc. Blog

Bollente Companies, Inc. News:

Bollente Companies' trutankless® Partners with Ferguson for Nationwide Distribution Program

Bollente Companies Increases Production and Distribution Capabilities for trutankless® with Global Manufacturing Partnership

Bollente Companies Increases Presence in Trending Segment of Commercial Construction with Its Smart trutankless Product Line

AV1 Group, Inc. (AVOP)

The QualityStocks Daily Newsletter would like to spotlight AV1 Group, Inc. (AVOP). Today, AV1 Group, Inc. closed trading at $0.0374, off by 1.58%, on 236,512 volume with 20 trades. The stock’s average daily volume over the past 60 days is 76,033 and its 52-week low/high is $0.017/$0.28.

AV1 Group, Inc. (AVOP), is a publicly traded investment and holding company established to identify, secure and monetize emerging growth companies in a number of sectors that include cannabis related technologies, grow houses and cultivation, and e-commerce businesses positioned for exponential growth. After identifying businesses displaying revolutionary concepts able to develop a substantial footprint in high-growth markets, the business model followed calls for incubating and supporting the best opportunities.

The company seeks to discover inspired entrepreneurs with innovative ideas that are poised for significant revenue generation. Management expertise can be seen in the development of embryonic-stage subsidiaries as the company brings a spectrum of backgrounds to the table with a significant resource of knowledge and experience to every venture. AV1 Group explores every opportunity to help each sector exceed its revenue goals while building close, active working relationships as it prepares each respective division to be a robust competitor within the various chosen markets.

AV1 Group companies include:

  • XFIRESmartSystems.com – Intelligent lighting solutions and wireless access for many different applications.
  • VaporHighUSA.com – Over 800 vaping products; bitcoin payments accepted.
  • DentalCannatizer.com – Revolutionary dual jet dental water jet integrates hemp oil infusing.
  • IntelligentLightingCorp.com – Comprehensive, energy-efficient lighting solutions.
  • CannaLighting.com – Wholly owned subsidiary building strategic relationships in the LED sector to provide solutions for grow houses and cultivation centers.
  • MJIQ – First, comprehensive, enterprise-grade integrated software suite being developed for the legal cannabis industry.
  • Hemptory.com – Engaging online destination for all hemp and cannabis related products and services.
  • Lawster.com – Puts consumers and small businesses in contact with legal services and service providers.
  • MJTestLabs.com – Under development website will serve cannabis dispensaries, laboratories and industry affiliates.

AV1 Group's business model delivers an advantage with internally-created projects that are poised for revenue generation and a cross-company revenue platform that enables the company to incubate and foster growth in early-stage subsidiaries under one umbrella. Disclaimer

AV1 Group, Inc. Blog

AV1 Group, Inc. News:

NetworkNewsWire Announces Publication Featuring Growth Opportunities for Innovators of Lighting Technologies

AV1 Group Announces Purchase Order from an Additional California Prison

AV1 Group, Inc. (AVOP) Engages NetworkNewsWire for Corporate Communications Solutions

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

MarketBeat
(PTSXQ) +2,080.69%

2.

MarketClub Analysis
(LINU) +134.59%

3.

Stock Commander
(ECEZ) +64.00%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251